Marianna Sassone
Overview
Explore the profile of Marianna Sassone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
225
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zappaterra A, Civettini I, Cafro A, Pezzetti L, Pierini S, Anghilieri M, et al.
Blood Transfus
. 2024 Feb;
22(4):328-337.
PMID: 38315530
Background: Induction with daratumumab-based regimens followed by autologous stem cell transplantation is the current standard for newly diagnosed multiple myeloma (NDMM) patients eligible for intensive chemotherapy. However, concerns emerged regarding...
2.
Conconi A, Chiappella A, Ferreri A, Stathis A, Botto B, Sassone M, et al.
Blood Adv
. 2024 Jan;
8(6):1541-1549.
PMID: 38181782
Primary testicular diffuse large B-cell lymphoma (PTL) is characterized by high risk of contralateral testis and central nervous system (CNS) relapse. Chemoimmunotherapy with intrathecal (IT) CNS prophylaxis and contralateral testis...
3.
Pirosa M, Sassone M, Kiesewetter B, Guillermo A, Devizzi L, Domingo Domenech E, et al.
Haematologica
. 2022 Dec;
108(6):1671-1675.
PMID: 36546422
No abstract available.
4.
Ferreri A, Angelillo P, Erbella F, Cattaneo C, Verga L, Lleshi A, et al.
Blood Adv
. 2022 May;
6(22):5811-5820.
PMID: 35580327
Patients with aggressive B-cell lymphoma and MYC rearrangement at fluorescence in situ hybridization exhibit poor outcome after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). In the last decade, 68 patients with...
5.
Visco C, Marcheselli L, Mina R, Sassone M, Guidetti A, Penna D, et al.
Blood Adv
. 2021 Oct;
6(1):327-338.
PMID: 34644385
Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease 2019 (COVID-19) during the course of HM have been described to have...
6.
Ferreri A, Calimeri T, Lopedote P, Francaviglia I, Daverio R, Iacona C, et al.
Br J Haematol
. 2021 Feb;
193(3):497-505.
PMID: 33620087
Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of...
7.
Ferreri A, Cattaneo C, Lleshi A, Verga L, Allione B, Facchetti F, et al.
Br J Haematol
. 2020 Oct;
192(1):119-128.
PMID: 33085777
A few prospective trials in HIV-positive patients with Burkitt lymphoma (BL) or high-grade B-cell lymphoma (HGBL) have been reported. Investigated therapies have shown good efficacy but relevant safety problems, with...
8.
Ferreri A, Calimeri T, Ponzoni M, Curnis F, Conte G, Scarano E, et al.
Blood Adv
. 2020 Aug;
4(15):3648-3658.
PMID: 32766857
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment of diffuse large B-cell lymphoma (DLBCL). Primary DLBCL of the central nervous system (CNS) (primary central nervous system lymphoma...
9.
Ferreri A, Sassone M, Angelillo P, Zaja F, Re A, Di Rocco A, et al.
Hematol Oncol
. 2020 May;
38(3):257-265.
PMID: 32356913
We report final results of a phase II trial addressing efficacy and feasibility of lenalidomide maintenance in patients with chemosensitive relapse of diffuse large B-cell lymphoma (DLBCL) not eligible for...
10.
Ferreri A, Sassone M, Miserocchi E, Govi S, Cecchetti C, Corti M, et al.
Blood Adv
. 2020 Mar;
4(6):1013-1019.
PMID: 32182364
Patients with indolent conjunctival lymphomas exhibit good prognosis, with exceptional cases of dissemination, and are suitable candidates for intralesional therapies. We report the first prospective phase 2 trial using intralesional...